OIS at AAO 2015

Iconic Therapeutics

Nov 12, 2015 12:05pm ‐ Nov 12, 2015 12:13pm


Iconic Therapeutics is a clinical stage biopharmaceutical company developing new therapeutics for retinal diseases and cancer. Iconic’s lead product candidate, ICON-1, a novel fusion protein that targets Tissue Factor, is in Phase 2 development for wet AMD. Iconic is backed by MPM Capital, H.I.G. Bioventures and Lundbeckfond Ventures.


You must be logged in and own this session in order to post comments.